Free Trial
NASDAQ:XCUR

Exicure Earnings Date & Estimates

Exicure logo
$1.08 +0.01 (+0.46%)
As of 03:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Exicure is estimated to report earnings on Monday, November 16, 2026, after market closes.

Upcoming Earnings Announcement

Announcement Date
Time
After Market Closes

What Analysts Expect from Exicure

Exicure is expected to post earnings of -$18.60 per share on revenue of $1.64 million. In the same quarter a year earlier Exicure reported -$0.39 per share. Exicure last reported on August 14, 2026, posting -$0.18 per share and beating the -$18.60 consensus estimate.

Consensus Estimates

Consensus EPS
-$18.60
Expected Revenue
$1.64 million
Prior-Year EPS
-$0.39

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.18 (Beat by +$18.42)

Exicure Earnings FAQ

Exicure (NASDAQ:XCUR) is estimated to report earnings on Monday, November 16, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Exicure to post earnings of -$18.60 per share for the quarter.

The consensus revenue estimate for Exicure is $1.64 million for the quarter.

Exicure Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Exicure (XCUR) Projected to Announce Earnings on Thursday
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity.

The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options.

Exicure was based in Chicago, Illinois. The company’s programs and business focus have changed over time, and detailed current information about its operations and leadership is limited.

View Exicure Profile